pfizer inc (PFE) Key Developments
Pfizer Eastern Europe Presents at 2015 Russian Pharmaceutical Forum, May-19-2015 06:35 PM
May 16 15
Pfizer Eastern Europe Presents at 2015 Russian Pharmaceutical Forum, May-19-2015 06:35 PM. Venue: Corinthia Hotel, Saint Petersburg, Russia. Speakers: Olga Krylova, Senior Director External R&D Innovation.
Marc Tessier-Lavigne to Step Down from Board of Directors of Pfizer Inc
May 14 15
Pfizer Inc. announced that Director Marc Tessier-Lavigne, Ph.D. has decided to step down from its Board of Directors on May 14, 2015. His decision is coincident with the launch of Denali, a new biotechnology company focused on developing effective therapies for neurodegenerative diseases. Dr. Tessier-Lavigne is a co-founder of Denali, and he will serve as the chairman of the company. Dr. Tessier-Lavigne was appointed to Pfizer’s board of directors in December 2011, and most recently served as a member of the Regulatory and Compliance Committee and Science and Technology Committee.
Pfizer Inc. Announces Executive Changes
May 6 15
Pfizer Inc. announced two strategic appointments in the leadership of the Worldwide Research and Development organization effective immediately. Michael D. Ehlers, M.D., Ph.D., has been selected as Group Senior Vice President and Head of BioTherapeutics Research & Development and Site Head for Cambridge and Boston, Massachusetts locations. Dr. Ehlers will report directly to Mikael Dolsten, M.D., Ph.D., President of Worldwide Research & Development. In addition, John Lin, M.D., Ph.D., has been selected as Senior Vice President and Chief Scientific Officer of Rinat. Dr. Lin will report directly to Robert T. Abraham, Ph.D., Group Senior Vice President for Oncology-Rinat Research & Development. In his expanded role as Head of BioTherapeutics Research & Development, Dr. Ehlers will continue to be Chief Scientific Officer of Pfizer's Neuroscience and Pain Research Unit and he will oversee the entire BioTherapeutics Research & Development organization. In connection with this appointment, the Inflammation and Immunology Research Unit will move to Pfizer's PharmaTherapeutics Research & Development organization. Dr. Ehlers will succeed José-Carlos Gutiérrez-Ramos, Ph.D., who has decided to return to the biotech sector in the Cambridge area.
23andMe, Inc. Launches Lupus Research Study in Collaboration with Pfizer Inc
May 5 15
23andMe, Inc. announced the launch of the Lupus Research Study in collaboration with Pfizer Inc. The companies aim to enroll 5,000 individuals with systemic lupus erythematosus, more commonly known as lupus, into the study to help better understand the genetics of lupus. The effort is also in collaboration with the Lupus Research Institute, and in concert with Lupus Awareness Month in May.
Pfizer Inc. Presents at NewYork BIO 25th Anniversary Conference 2015, May-04-2015 through May-05-2015
May 4 15
Pfizer Inc. Presents at NewYork BIO 25th Anniversary Conference 2015, May-04-2015 through May-05-2015. Venue: Time Warner Center, New York, United States. Presentation Date & Speakers: May-04-2015, Sandra Engle, Senior Principal Scientist. May-05-2015, Cyndi Green, Senior Director, Worldwide Business Development.